Pharmaceuticals, Biotechnology and Life Sciences
The growing incidence of more Western lifestyle diseases such as cardiovascular disease (CVD), cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8 billion in 2019.
Faron Pharmaceuticals has recruited first patient in the Phase II INFORAAA clinical trial of Traumakine for the treatment of Multi-Organ Failure (MOF) and mortality prevention of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
Risperdal lawsuits involving Johnson & Johnson medication to gynecomastia, (male breast growth) and other side effects allegedly associated with use of the atypical antipsychotic medication continue to move forward in the Philadelphia Court of Common Pleas, said Bernstein Liebhard LLP is a New York-based law firm representing the victims of defective drugs and medical devices in USA.
London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.
AbbVie plans to it increase its earnings per share and elevates the market value of the remaining shares, as it has authorized a $5 billion increase to AbbVie’s existing stock repurchase program.
Jansen revealed results from its real-world study of its cancer drug Zytiga in combination with Prednisone, to treat men with prostate cancer.
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).